IP Group and V-Bio have backed a round that will support phase 2 trials for a treatment for diabetic macular edema.

Oxular, a UK-based retinal therapeutics developer, received $37m in a funding round yesterday backed by commercialisation firm IP Group and V-Bio Ventures, a venture fund affiliated with VIB. Venture capital firm Forbion Capital Partners led the round, which also featured investment firm NeoMed. Founded in 2014 as Precision Ocular, Oxular is developing therapies for retinal…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.